Scarica l'app Stockscreener
42.44
4.25%
1.73
Precedente Chiudi:
$40.71
Aprire:
$40.26
Volume 24 ore:
708.68K
Relative Volume:
0.72
Capitalizzazione di mercato:
$3.42B
Reddito:
-
Utile/perdita netta:
$-64.16M
Rapporto P/E:
-33.41
EPS:
-1.2702
Flusso di cassa netto:
$-69.06M
1 W Prestazione:
+3.49%
1M Prestazione:
-1.44%
6M Prestazione:
+61.86%
1 anno Prestazione:
+31.23%
Intervallo 1D:
$40.06
$42.55
Intervallo di 1 settimana:
$39.20
$44.56
Portata 52W:
$14.80
$45.56
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Confronta CGON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
42.44 | 3.28B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-05-02 | Iniziato | JP Morgan | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Perform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
FY2026 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will CG Oncology Inc. stock deliver strong dividend growthJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
How CG Oncology Inc. stock reacts to inflationary pressuresWeekly Loss Report & Accurate Technical Buy Alerts - newser.com
CG Oncology (NASDAQ:CGON) Director Sells $41,430.00 in Stock - MarketBeat
Price action breakdown for CG Oncology Inc.2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
CG Oncology Inc. stock outlook for YEARPortfolio Return Report & Weekly Market Pulse Updates - newser.com
CG Oncology, Inc. Stocks Surge Amid Positive Developments - TipRanks
Midday Stock Roundup: Eledon Falls after Trial Report - Orange County Business Journal
CG Oncology, Inc. $CGON Holdings Decreased by Los Angeles Capital Management LLC - MarketBeat
New CEOs for AdvanCell, Sonoma - BioCentury
RBC Capital Maintains CG Oncology (CGON) Outperform Recommendation - Nasdaq
CG Oncology stock rises as RBC Capital raises price target on BLA filing progress - Investing.com Canada
Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says - MarketScreener
CG Oncology price target raised to $61 from $53 at RBC Capital - TipRanks
Morgan Stanley Raises Price Target to CG Oncology to $82 From $79, Keeps Overweight Rating - MarketScreener
CG Oncology Plans To Complete BLA Submission For Cretostimogene In Bladder Cancer In 2026 - Nasdaq
CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation - TipRanks
CG Oncology (NASDAQ:CGON) Releases Earnings Results, Meets Expectations - MarketBeat
How moving averages guide CG Oncology Inc. tradingJuly 2025 Levels & Daily Oversold Bounce Ideas - newser.com
What the charts say about CG Oncology Inc. today2025 Buyback Activity & Free Long-Term Investment Growth Plans - newser.com
Why retail investors favor CG Oncology Inc. stockQuarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
CG Oncology Inc Stock Analysis and ForecastSwing Trading Ideas & Low Risk Wealth Building - earlytimes.in
Will CG Oncology Inc. stock recover faster than market2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders - Yahoo Finance
CG Oncology (NASDAQ:CGON) Trading 6.3% HigherWhat's Next? - MarketBeat
Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc. - TipRanks
CG Oncology’s Impressive Q3 Revenue Surpass Amplifies Investor Interest - timothysykes.com
Sentiment analysis tools applied to CG Oncology Inc.Bond Market & AI Forecasted Entry and Exit Points - newser.com
Why CG Oncology Inc. stock attracts global investorsJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Candriam S.C.A. Takes Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
CG Oncology announces 7.3M share offering - MSN
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology Advances Bladder Cancer Therapy Development - TipRanks
Wellington Management Group LLP Increases Stake in CG Oncology I - GuruFocus
Market reaction to CG Oncology Inc.’s recent newsMarket Growth Report & Reliable Price Breakout Alerts - newser.com
CG Oncology’s Promising Developments and Competitive Edge Drive Buy Rating - TipRanks
CG Oncology Appoints Jim DeTore as Interim CFO - TipRanks
Robert Lapetina resigned as CG Oncology's interim financial officer on Nov 10SEC filing - MarketScreener
CG Oncology, Inc. Announces Principal Financial and Accounting Officer Changes - MarketScreener
CG Oncology expects cash to fund operations into 1H of 2028 - TipRanks
Buy Rating Affirmed for CG Oncology: Promising Advancements and Market Potential of Cretostimogene - TipRanks
CG Oncology price target lowered to $60 from $62 at BofA - TipRanks
CG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Why CG Oncology, Inc. Stocks Are Rising - TipRanks
CG Oncology reports Q3 EPS (57c), consensus (55c) - TipRanks
CG Oncology Q3 Net Loss Widens; Revenue Rises - MarketScreener
Earnings Flash (CGON) CG Oncology, Inc. Reports Q3 Revenue $1.7M - MarketScreener
Earnings Flash (CGON) CG Oncology Posts Q3 Net Loss $0.57 a Share, vs. FactSet Est of $0.57 Loss - MarketScreener
CG Oncology Initiates Rolling BLA Submission for Cretostimogene Monotherapy in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Quiver Quantitative
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):